Corcept Therapeutics Incorporated (CORT) Modifies Revenue Guidance while Banking on Cushing Syndrome Treatment for Growth [Yahoo! Finance]
Corcept Therapeutics (NASDAQ:CORT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $145.00 price target on the stock.
Corcept Therapeutics (NASDAQ:CORT) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
Corcept Therapeutics (NASDAQ:CORT) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Corcept (NASDAQ:CORT) [Yahoo! Finance]